ESMO WCGIC 2023 | The benefits and pitfalls of total neoadjuvant therapy in rectal cancer

Jeroen Dekervel, MD, PhD, KU Leuven, Leuven, Belgium, discusses the emerging role of total neoadjuvant therapy for patients with rectal cancer. Various clinical trials have demonstrated the superiority of total neoadjuvant therapy, where it has improved disease-free survival and overall survival. However, caution needs to be exercised, since not all patients will have metastatic disease and consequently not need such intense treatment. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.